Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759343 | 0.84 | MAPT (0.54) | ESR1ESR2MAPTTRPA1NPC1 | |
| SCHEMBL4399692 | 0.79 | CHRNB2 (0.45) | ESR1ESR2MAPTCHRNA7HTR3A | |
| SCHEMBL2137945 | 0.79 | ESR1 (0.61) | ESR1ESR2MAPTHSP90AA1ALOX15 | |
| SCHEMBL8233882 | 0.76 | F9 (0.47) | ESR1ESR2MAPTCHRNA7HTR3A | |
| SCHEMBL8290795 | 0.76 | ESR1 (0.41) | ESR1ESR2HSP90AA1 | |
| SCHEMBL23474002 | 0.76 | MAPT (0.42) | ESR1ESR2MAPTHSP90AA1CHRNA7 | |
| SCHEMBL25591522 | 0.76 | CHRNA7 (0.40) | ESR1ESR2MAPTHSP90AA1CHRNA7 | |
| SCHEMBL5514251 | 0.76 | ACHE (0.41) | ESR1ESR2HSP90AA1CHRNA7HTR3A | |
| SCHEMBL1836503 | 0.76 | ALDH1A1 (0.49) | ESR1ESR2MAPTHSP90AA1CHRNA7 | |
| SCHEMBL5512412 | 0.76 | ESR1 (0.42) | ESR1ESR2HSP90AA1ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2562170-B1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO LTD (JP) | 2014-10-29 | — | — | EP | claimed |
| EP-2562170-A1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-27 | — | — | EP | claimed |
| US-8017789-B2 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-OXO-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl]methoxy]phenyl]proprionate ester and intermediate for the process | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | claimed |
| US-20090099369-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-16 | — | — | US | claimed |
| EP-1988085-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BEZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-11-05 | — | — | EP | claimed |
| EP-3122750-B1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| WO-2017050732-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017050792-A1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
| EP-1988085-B1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-HYDROXY-1,2-BEZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | TOYAMA CHEMICAL CO LTD (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2562170-B1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO LTD (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2562170-B1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO LTD (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2562170-A1 | Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate for the process | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-02-27 | — | — | EP | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | DDO, DAO, CACNA1S | ESR1 2250/4885ESR2 3052/4885MAPT 1006/4885 |
| US-20090099369-A1 | PROCESS FOR PRODUCTION OF 3-[5-[4-(CYCLOPENTYLOXY)-2-HYDROXYBENZOYL]-2-[(3-OXO-2-SUBSTITUTED-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)METHOXY]PHENYL]PROPIONATE ESTER AND INTERMEDIATE FOR THE PROCESS | HPD, HAO2, HAAO | ESR1 4464/4885ESR2 2828/4885MAPT 3961/4885 |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | ESR1 2101/4885ESR2 463/4885MAPT 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.